Leerink Partnrs Weighs in on Compass Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) – Analysts at Leerink Partnrs upped their Q2 2024 earnings estimates for Compass Therapeutics in a research report issued on Monday, May 13th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.11) per share for the quarter, up from their prior estimate […]

Related Keywords

United States ,Leerink Partnrs ,Nasdaq ,Cm Management ,Element Capital Management ,Blackstone Inc ,Compass Therapeutics Company Profile ,Compass Therapeutics Inc ,Compass Therapeutics ,Free Report ,Compass Therapeutic ,Get Free Report ,Capital Management ,Pale Fire Capital ,Fire Capital ,Compass Therapeutics Daily ,